|
Status |
Public on Jun 27, 2006 |
Title |
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by array
|
Summary |
The molecular biology of metastatic potential in melanoma has been studied many times previously and changes in the expression of many genes have been linked to metastatic behaviour. What is lacking is a systematic characterization of the regulatory relationships between genes whose expression is related to metastatic potential. Such a characterization would produce a molecular taxonomy for melanoma which could feasibly be used to identify epigenetic mechanisms behind changes in metastatic behaviour. To achieve this we carried out three separate DNA microarray analyses on a total of 86 cultures of melanoma. Significantly, multiple testing correlation revealed that previous reports describing correlations of gene expression with activating mutations in BRAF or NRAS were incorrect and that no gene expression patterns correlate with the mutation status of these MAPK pathway components. Instead, we identified three different sample cohorts (A, B and C) and found that these cohorts represent melanoma groups of differing metastatic potential. Cohorts A and B were susceptible to TGFbeta-mediated inhibition of proliferation and had low motility. Cohort C was resistant to TGFb and demonstrated high motility. Meta-analysis of the data against previous studies linking gene expression and phenotype confirmed that cohorts A and C represent transcription signatures of weakly and strongly metastatic melanomas, respectively. Gene expression co-regulation suggested that signalling via TGFbeta-type and Wnt pathways underwent considerable change between cohorts. These results suggest a model for the transition from weakly to strongly metastatic melanomas in which TGFbeta-type signalling upregulates genes expressing vasculogenic/extracellular matrix remodeling factors and Wnt signal inhibitors, coinciding with a downregulation of genes downstream of Wnt signalling.
This SuperSeries is composed of the SubSeries listed below.
|
|
|
Overall design |
Refer to individual Series
Zurich: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4840 Philadelphia: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4841 Mannheim: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4843
|
|
|
Contributor(s) |
Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, Weber BL, Nathanson KL, Phillips DJ, Herlyn M, Schadendorf D, Dummer R |
Citation(s) |
16827748, 19213840 |
|
Submission date |
May 15, 2006 |
Last update date |
Nov 08, 2019 |
Contact name |
Keith S Hoek |
E-mail(s) |
keith.hoek@usz.ch
|
URL |
http://www.jurmo.ch/work.html
|
Organization name |
Currently unaffilliated
|
Street address |
private
|
City |
Zürich |
ZIP/Postal code |
8004 |
Country |
Switzerland |
|
|
Platforms (3) |
GPL96 |
[HG-U133A] Affymetrix Human Genome U133A Array |
GPL97 |
[HG-U133B] Affymetrix Human Genome U133B Array |
GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
|
Samples (105)
|
|
This SuperSeries is composed of the following SubSeries: |
GSE4840 |
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature (Zürich). |
GSE4841 |
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature (Philadelphia). |
GSE4843 |
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature (Mannheim). |
|
Relations |
BioProject |
PRJNA95841 |